Valeant Pharmaceuticals (VRX) Makes Monster Profits From Early 2017 Disposals
Learn Bonds | January 16, 2017
Forging into 2017, analysts continue to cite Valeant Pharmaceutical Intl. Inc.’s (NYSE:VRX) debt, public image and reduced influence among its biggest challenges. The drug maker is now set on regaining portions of the confidence it lost during the last two years. Valeant shares rose to great peaks back in July 2015. A number of setbacks have since gradually chipped away at its all-time highs, and persist to the current day.